INCLINE VILLAGE, Nev., Feb. 14, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's chief executive officer, will present at the following two upcoming investor conferences:
2018 RBC Capital Markets Global Healthcare Conference
Wednesday February 21, 2018 at 9:30 a.m. EST
New York City
Cowen and Company 38th Annual Health Care Conference
Tuesday, March 13, 2018 at 12:00 p.m. EDT
To access the live and subsequently archived webcast of these presentations, go to the company's website at http://www.pdl.com and go to "Presentations and Events." Please connect to the website at least 15 minutes prior to the presentations to allow for any software download that may be necessary. The archived webcasts will be available for at least seven days following the presentations.
About PDL BioPharma
PDL seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. In 2012, PDL began providing alternative sources of capital through royalty monetizations and debt facilities, and in 2016, began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. To date, PDL has consummated 17 such transactions, of which nine are active and outstanding. PDL has one debt transaction outstanding, representing deployed and committed capital of $20.0 million: CareView; one hybrid royalty/debt transaction outstanding, representing deployed and committed capital of $44.0 million: Wellstat Diagnostics; and five royalty transactions outstanding, representing deployed and committed capital of $396.1 million and $397.1 million, respectively: KYBELLA®, AcelRx, University of Michigan, Viscogliosi Brothers and Depomed. PDL's equity and loan investments in Noden represent deployed and committed capital of $179.0 million and $202.0 million, respectively, and its converted equity and loan investment in LENSAR represents deployed capital of $40 million.
NOTE: PDL, PDL BioPharma, the PDL logo and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary, to PDL BioPharma, Inc. which reserves all rights therein.
SOURCE PDL BioPharma, Inc.